Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial
0
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Limited data are available regarding the efficacy of rivaroxaban for the treatment of cancer-associated venous thromboembolism (VTE). The aim of this study was to evaluate the effectiveness and safety of rivaroxaban for the treatment of VTE in active cancer patients. Methods: In this prospective, multicenter, open-label trial (NCT01989845), we enrolled patients with active cancer and objectively diagnosed lower-extremity deep vein thrombosis, pulmonary embolism (PE), or both from November 2013 to June 2016. Active cancer was defined as a histologically confirmed malignancy, which was diagnosed or treated within the previous 6 months, or as a recurrent/ metastatic cancer. Patients received oral rivaroxaban 15 mg twice daily for first 3 weeks, followed by 20 mg once daily for 6 months. The primary outcome was the symptomatic recurrent VTE and the secondary outcomes included any recurrent VTE, major or clinically relevant non-major (CRNM) bleeding events, and overall mortality. All study outcomes were validated by blinded central adjudication. Results: Of 124 patients enrolled, 110 (88.7%) had solid cancer, 93 (75.0%) had metastatic disease, and 110 (88.7%) were receiving chemotherapy or radiotherapy. During the 6-month study period, seven patients experienced symptomatic recurrent VTE (cumulative incidence, 5.9%), and two patients experienced incidental recurrent PE (cumulative incidence of any recurrent VTE, 7.6%). Major bleeding events occurred in six patients (cumulative incidence, 5.3%) and CRNM bleeding events in 11 patients (cumulative incidence, 10.2%). Twenty-eight patients (overall mortality, 24.0%) died. Conclusions: Rivaroxaban is effective and safe for the treatment of VTE in patients with active cancer.
Abstract
Background/Aims: Limited data are available regarding the efficacy of rivaroxaban for the treatment of cancer-associated venous thromboembolism (VTE). The aim of this study was to evaluate the effectiveness and safety of rivaroxaban for the treatment of VTE in active cancer patients. Methods: In this prospective, multicenter, open-label trial (NCT01989845), we enrolled patients with active cancer and objectively diagnosed lower-extremity deep vein thrombosis, pulmonary embolism (PE), or both from November 2013 to June 2016. Active cancer was defined as a histologically confirmed malignancy, which was diagnosed or treated within the previous 6 months, or as a recurrent/ metastatic cancer. Patients received oral rivaroxaban 15 mg twice daily for first 3 weeks, followed by 20 mg once daily for 6 months. The primary outcome was the symptomatic recurrent VTE and the secondary outcomes included any recurrent VTE, major or clinically relevant non-major (CRNM) bleeding events, and overall mortality. All study outcomes were validated by blinded central adjudication. Results: Of 124 patients enrolled, 110 (88.7%) had solid cancer, 93 (75.0%) had metastatic disease, and 110 (88.7%) were receiving chemotherapy or radiotherapy. During the 6-month study period, seven patients experienced symptomatic recurrent VTE (cumulative incidence, 5.9%), and two patients experienced incidental recurrent PE (cumulative incidence of any recurrent VTE, 7.6%). Major bleeding events occurred in six patients (cumulative incidence, 5.3%) and CRNM bleeding events in 11 patients (cumulative incidence, 10.2%). Twenty-eight patients (overall mortality, 24.0%) died. Conclusions: Rivaroxaban is effective and safe for the treatment of VTE in patients with active cancer.
참고문헌 (35)
- Young A, "Thrombosis and cancer", Nat Rev Clin Oncol, 9, pp.437~449 (2012)
- Lee AY, "Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer", N Engl J Med, 349, pp.146~153 (2003)
- Lee AYY, "Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer : a randomized clinical trial", JAMA, 314, pp.677~686 (2015)
- Kearon C, "Antithrombotic therapy for VTE disease : CHEST guideline and expert panel report", Chest, 149, pp.315~352 (2016)
- Lyman GH, "Venous thromboembolism prophylaxis and treatment in patients with cancer : American Society of Clinical Oncology clinical practice guideline update", J Clin Oncol, 31, pp.2189~2204 (2013)
- Mandala M, "Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines", Ann Oncol, (22 Suppl 6), pp.vi85~vi92 (2011)
- Farge D, "International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer", Lancet Oncol, 17, pp.e452~e466 (2016)
- Lee AY, "Treatment of cancer-associated thrombosis", Blood, 122, pp.2310~2317 (2013)
- Schulman S, "Dabigatran versus warfarin in the treatment of acute venous thromboembolism", N Engl J Med, 361, pp.2342~2352 (2009)
- EINSTEIN-PE Investigators, "Oral rivaroxaban for the treatment of symptomatic pulmonary embolism", N Engl J Med, 366, pp.1287~1297 (2012)
- EINSTEIN Investigators, "Oral rivaroxaban for symptomatic venous thromboembolism", N Engl J Med, 363, pp.2499~2510 (2010)
- Agnelli G, "Oral apixaban for the treatment of acute venous thromboembolism", N Engl J Med, 369, pp.799~808 (2013)
- Hokusai-VTE Investigators, "Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism", N Engl J Med, 369, pp.1406~1415 (2013)
- Agnelli G, "Oral apixaban for the treatment of venous thromboembolism in cancer patients : results from the AMPLIFY trial", J Thromb Haemost, 13, pp.2187~2191 (2015)
- Prins MH, "Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer(EINSTEIN-DVT and EINSTEIN-PE) : a pooled subgroup analysis of two randomized controlled trials", Lancet Haematol, 1, pp.e37~e46 (2014)
- Raskob GE, "Edoxaban for venous thromboembolism in patients with cancer : results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial", Lancet Haematol, 3, pp.e379~e387 (2016)
- Schulman S, "Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer", Thromb Haemost, 114, pp.150~157 (2015)
- 임호영, "Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism", Blood Research, 49(2), pp.77~79 (2014), 대한혈액학회
- Piran S, "Management of venous thromboembolism:an update", Thromb J, 14(Suppl 1), pp.23~ (2016)
- Louzada ML, "Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism", Circulation, 126, pp.448~454 (2012)
- Schulman S, "Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients", J Thromb Haemost, 3, pp.692~694 (2005)
- Ay C, "Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality", J Thromb Haemost, 13, pp.390~397 (2015)
- van der Hulle T, "Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism", J Thromb Haemost, 12, pp.1116~1120 (2014)
- Jang MJ, "Incidence of venous thromboembolism in Korea : from the Health Insurance Review and Assessment Service database", J Thromb Haemost, 9, pp.85~91 (2011)
- Yhim HY, "Incidence of venous thromboembolism following major surgery in Korea : from the Health Insurance Review and Assessment Service database", J Thromb Haemost, 12, pp.1035~1043 (2014)
- Lee KW, "The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer", J Thromb Haemost, 8, pp.540~547 (2010)
- Yhim HY, "The incidence, risk factors, and prognosis of recurrent venous thromboembolism(VTE)in patients with advanced solid cancers receiving anticoagulation therapy after the diagnosis of index VTE", Thromb Res, 131, pp.e133~e140 (2013)
- den Exter PL, "Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism : a comparison with symptomatic patients", J Clin Oncol, 29, pp.2405~2409 (2011)
- van der Hulle T, "Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients : a pooled analysis of 926 patients", J Thromb Haemost, 14, pp.105~113 (2016)
- Chai-Adisaksopha C, "The impact of bleeding complications in patients receiving target-specific oral anticoagulants : a systematic review and meta-analysis", Blood, 124, pp.2450~2458 (2014)
- Schulman S, "Management of bleeding complications in patients with cancer on DOACs", Thromb Res, (140 Suppl 1), pp.S142~S147 (2016)
- Desai J, "Gastrointestinal bleeding with the new oral anticoagulants : defining the issues and the management strategies", Thromb Haemost, 110, pp.205~212 (2013)
- Kearon C, "Management of anticoagulation before and after elective surgery", N Engl J Med, 336, pp.1506~1511 (1997)
- Francis CW, "Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months : the DALTECAN Study", J Thromb Haemost, 13, pp.1028~1035 (2015)
- Raskob GE, "Edoxaban for the treatment of cancer-associated venous thromboembolism", N Engl J Med, 378, pp.615~624 (2018)